Arranon, Atriance(nelarabine)
Arranon, Atriance (nelarabine) is a small molecule pharmaceutical. Nelarabine was first approved as Arranon on 2005-10-28. It is used to treat t-cell leukemia in the USA. It has been approved in Europe to treat precursor t-cell lymphoblastic leukemia-lymphoma.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Trade Name
FDA
EMA
Arranon (generic drugs available since 2021-11-17)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nelarabine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARRANON | Sandoz | N-021877 RX | 2005-10-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arranon | New Drug Application | 2020-06-11 |
| nelarabine | ANDA | 2023-03-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| t-cell leukemia | — | D015458 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9261 | Injection, nelarabine, 50 mg |
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 1 | 1 | — | — | 1 | 3 | |
| Adult t-cell leukemia-lymphoma | D015459 | C91.5 | — | 2 | — | — | — | 2 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 1 | — | — | — | 1 | |
| T-cell leukemia | D015458 | — | 1 | — | — | — | 1 | ||
| B-cell leukemia | D015448 | — | 1 | — | — | — | 1 | ||
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | 1 | 1 | — | — | — | 1 | ||
| Biphenotypic leukemia acute | D015456 | C95.0 | — | 1 | — | — | — | 1 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 1 | — | — | — | 1 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | — | 1 | — | — | — | 1 | |
| Follicular lymphoma | D008224 | C82 | — | 1 | — | — | — | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NELARABINE |
| INN | nelarabine |
| Description | Nelarabine is a purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G). It has a role as an antineoplastic agent, a DNA synthesis inhibitor and a prodrug. It is a purine nucleoside, a beta-D-arabinoside and a monosaccharide derivative. It is functionally related to a guanine and a 9-beta-D-arabinofuranosylguanine. |
| Classification | Small molecule |
| Drug class | antineoplastics (arabinofuranosyl derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 121032-29-9 |
| RxCUI | 274771 |
| ChEMBL ID | CHEMBL1201112 |
| ChEBI ID | 63612 |
| PubChem CID | 3011155 |
| DrugBank | DB01280 |
| UNII ID | 60158CV180 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 852 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arranon, Nelarabine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
514 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more